
Last year in the UK over 60,000 cancer patients enrolled on clinical trials aimed at improving cancer treatments and making them available to all.
Please note - this trial is no longer recruiting patients. We hope to add results when they are available.
This trial is looking at a drug called denosumab with chemotherapy for non small cell lung cancer. It is for people with non small cell lung cancer (NSCLC) that has spread to another part of their body.
Doctors can treat NSCLC with chemotherapy. They usually use a , such as cisplatin or carboplatin alongside another chemotherapy drug. In this trial, they are looking at adding a drug called denosumab.
Denosumab is a type of biological therapy called a monoclonal antibody. Doctors use it to treat cancer that has spread to the bones or to delay it spreading to the bones.
The researchers want to find out more about how denosumab works in people with NSCLC. They also want to find out about how denosumab works alongside platinum chemotherapy drugs.
The researchers will look at certain substances () in your cancer tissue and blood.
The main aim of this trial is to find out if there is a link between the biomarkers and how well the combination of denosumab and platinum chemotherapy works for NSCLC.
You may be able to join this trial if all of the following apply. You
You cannot join this trial if any of these apply
This is an international phase 2 trial. The researchers need 216 people to join.
It is a randomised trial. The people taking part are put into treatment groups by a computer. Neither you nor your doctor will be able to decide which group you are in. And neither of you will know which group you are in. This is called a double blind trial.
You have denosumab (or the dummy drug) as injections under your skin. You have the chemotherapy drugs as injections into a vein. You have treatment every 3 or 4 weeks, between 4 and 6 times.
When you finish chemotherapy, you can continue to have denosumab (or dummy drug) alone as long as your doctor thinks it is helping you and the side effects aren’t too bad. You have it every 3 or 4 weeks.
The researchers will ask for a sample of your cancer that was removed when you had surgery or a . They will also take some extra blood samples. They will use these to find out what happens to denosumab in the body. They may also use these samples in future research.
You see the doctor and have some tests before you take part in this trial. The tests include
During treatment you see the doctor every 3 to 4 weeks depending on how often you have treatment. You have a bone scan and CT scan or MRI scan every 6 weeks for 11 months and then about every 3 months until your cancer starts to grow again.
If your cancer starts to grow during treatment you see the doctor every 3 to 4 weeks for treatment but you will have no further scans.
When you finish treatment you see the doctor every 3 months.
The most common side effects of denosumab are
We have more information on denosumab. We also have information on the side effects of chemotherapy for lung cancer.
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Dr Conrad Lewanski
Amgen
Experimental Cancer Medicine Centre (ECMC)
NIHR Clinical Research Network: Cancer
Freephone 0808 800 4040
Last year in the UK over 60,000 cancer patients enrolled on clinical trials aimed at improving cancer treatments and making them available to all.